# CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

> **NCT07234110** · NA · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed and Refractory CD5 Hematological Tumors

## Interventions

- **DRUG:** Fully human CD5 chimeric antigen receptor T cell injection

## Key facts

- **NCT ID:** NCT07234110
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-03
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234110, "CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07234110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*